

## INFORMATION

# PRECEPTORSHIP

## Acute Myeloid Leukemia

Coordinator: Dr. Francesc Bosch

 April 14<sup>th</sup> and 15<sup>th</sup>, 2026

 **Auditorio Cellex**  
C/ Natzaret, 115-117, 08035, Barcelona

### How to get:

 **L3** Vall d'Hebron

 Lines **19** and **76**

[www.vhio.net](http://www.vhio.net)

# PRECEPTORSHIP

## Acute Myeloid Leukemia

April 14<sup>th</sup>-15<sup>th</sup> | 2026

Coordinators:

**Dr. Francesc Bosch**

**Dr. Ana Pérez and Dr. Olga Salamero**

Sponsored by:



Technical Secretary:



Organized by:



# PRECEPTORSHIP

## Acute Myeloid Leukemia

Day 1 | Tuesday, April 14<sup>th</sup>

- 9:00 - 9:30 h • **AML diagnosis: Does blast count matter? (Hematology lab).** Julia Montoro
- 10:00 - 10:30 h • **Molecular implications in AML diagnosis: elderly vs younger (Hematology lab).** Andrés Jerez
- 10:30 - 11:00 h • **Coffee**
- 11:00 - 11:30 h • **Current treatment in fit patients with AML: Spanish and Europe drugs access and restrictions.** Ana Perez, Olga Salamero
- 11:30 - 12:00 h • **Who to transplant with AML? Evidence based indications.** Ana Perez, Olga Salamero
- 12:00 - 12:45 h • **Hematology lab round.** Julia Montoro, Andrés Jerez (GENERAL HOSPITAL)
- 13:00 - 14:00 h • **Transplant Multidisciplinary Committee.** Presencial session (ROOM JBUENO)
- 14:15 - 15:00 h • **Lunch** (ROOM JBUENO)
- 15:00 - 15:30 h • **Are there alternatives to transplant for long term survival in AML? (Interactive Q and A).** Ana Perez, Olga Salamero (ROOM JBUENO)

AML preceptorship program at Vall d' Hebron  
University Hospital, VHIO

**Coordinators:** Ana Pérez, Olga Salamero,  
Francesc Bosch

Day 2 | Wednesday, April 15<sup>th</sup>

- 9:00 - 9:30 h • **Novel trials in AML.** Alba Puyuelo
- 9:30 - 10:00 h • **Coffee**
- 10:00 - 11:00 h • **AML clinical cases discussion.** Irene Medina, Olga Salamero
- 11:00 - 11:30 h • **Detection of residual disease in AML and implications: is very deep sensitivity better?** Fran Beas or Maria Gabarros (to be confirmed)
- 11:30 - 12:30 h • **AML clinical cases management with detectable residual disease (Interactive Q and A)** Sandra Novoa, Ana Perez
- 12:30 - 13:30 h • **VISIT to the facilities: Clinical Trials and Advanced Therapy Unit.** Alba Puyuelo, Irene Medina (GENERAL HOSPITAL)
- 13:30 - 14:30 h • **Myeloid Malignancies Multidisciplinary Committee.** Presencial session & Lunch (ROOM JBUENO)
- 14:30 - 15:00 h • **Closing remarks and farewell**

